United States Biomarkers Market Industry: Market Size & Forecast 2026

The U.S. biomarkers market encompasses a wide range of products including discovery tools, diagnostic kits, imaging biomarkers, and bioinformatics platforms used by pharmaceutical companies, clinical laboratories, and research institutions. It represents the largest single-country share of the North American market, driven by substantial healthcare spending, a strong biopharmaceutical pipeline, and one of the world's most advanced clinical research infrastructures. Key application areas include companion diagnostics for targeted cancer therapies, disease progression monitoring, and drug development support.

• •Market valued at approximately $28.63 billion in 2025 with a 12.05% projected CAGR through the forecast period
• •Primary applications span oncology, cardiovascular disease, neurology, infectious disease, and immunology diagnostics
• •Strong investment in research and development from both pharmaceutical companies and government agencies such as the NIH

The accelerating shift toward precision and personalized medicine is a dominant force, as biomarkers enable therapies to be matched to individual patient profiles based on genetic and molecular characteristics. Rising cancer incidence and an aging U.S. population are increasing demand for early detection and companion diagnostics, while advances in high-throughput screening, next-generation sequencing, and artificial intelligence are lowering the cost and complexity of biomarker discovery. Additionally, regulatory support from the FDA for biomarker-based drug development pathways and expanded reimbursement coverage for companion diagnostics are reinforcing market expansion.

• •Precision medicine initiatives and companion diagnostic requirements for targeted therapies continue to expand
• •Technological advances in genomics, proteomics, and liquid biopsy enable discovery of novel biomarkers at lower cost
• •Growing burden of chronic diseases and cancer incidence rates drive demand for early detection tools

The market is commonly segmented by product type, including consumables (kits, reagents), instruments, and services, as well as by disease application, with oncology representing the largest segment due to the high volume of biomarker-driven cancer therapies in development and clinical use. By discovery technology, segments include genomics, proteomics, metabolomics, and imaging-based biomarkers, with genomics and liquid biopsy technologies among the fastest growing. Within North America, the U.S. dominates due to its concentration of biotechnology and pharmaceutical companies, world-class research universities, favorable regulatory pathways, and significant venture capital and institutional funding for biomarker research.

• •Oncology applications account for the largest market share, driven by companion diagnostics and immuno-oncology drug development
• •Genomics-based biomarkers, including next-generation sequencing and PCR technologies, represent the leading discovery platform segment
• •The U.S. comprises the dominant portion of North American market share, with Canada and Mexico contributing smaller but growing shares

What are the recent trends and outlook?

Liquid biopsy, which uses circulating tumor DNA and other biomarkers from blood samples rather than invasive tissue biopsies, is one of the most actively pursued technological frontiers and is expected to reshape oncology diagnostics. Multi-omics approaches that integrate genomics, proteomics, metabolomics, and transcriptomics data are gaining traction for more comprehensive biomarker panels. Artificial intelligence and machine learning are increasingly applied to biomarker identification from complex biological datasets, while point-of-care biomarker testing and wearable sensor technologies are creating new consumer-facing opportunities. Over the forecast horizon, continued FDA support for breakthrough therapy designations and expanded biomarker-drug co-development frameworks are likely to sustain the market's double-digit growth trajectory.

• •Liquid biopsy and circulating tumor DNA-based biomarkers are rapidly gaining clinical adoption for cancer monitoring
• •AI-driven biomarker discovery and multi-omics integration are accelerating the identification of novel diagnostic and prognostic indicators
• •Regulatory pathways supporting biomarker qualification and companion diagnostic co-development with therapeutics are expected to expand